Stock A388870 PHAROS IBIO CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Pharos iBio Co., Ltd.

Equities

A388870

KR7388870008

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 27/06/2024 BST 		5-day change 1st Jan Change
10,750 KRW +1.22% Intraday chart for Pharos iBio Co., Ltd. -9.36% -27.51%
2023 Pharos Therapeutics INC announced that it has received KRW 1.3523 billion in funding from Pharos iBio Co., Ltd. CI
2023 Pharos Therapeutics INC announced that it expects to receive KRW 1.3523 billion in funding from Pharos iBio Co., Ltd. CI

Valuation

Fiscal Period: December 2023
Capitalization 1 191,588
Enterprise Value (EV) 1 166,406
P/E ratio -20.3 x
Yield -
Capitalization / Revenue -
EV / Revenue -
EV / EBITDA -17.6 x
EV / FCF -26,831,710 x
FCF Yield -0%
Price to Book 6.76 x
Nbr of stocks (in thousands) 12,919
Reference price 2 14,830
Announcement Date 20/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales 1 421.1 187.7 57 300 -
EBITDA 1 -2,632 -5,891 -8,056 -10,041 -9,432
EBIT 1 -2,749 -6,047 -8,406 -10,619 -10,117
Operating Margin -652.76% -3,221.87% -14,747.26% -3,539.83% -
Earnings before Tax (EBT) 1 -4,951 -13,398 -31,471 -17,062 -8,858
Net income 1 -4,951 -13,398 -31,471 -17,062 -8,858
Net margin -1,175.82% -7,138.82% -55,211.94% -5,687.23% -
EPS 2 -892.0 -2,370 -5,423 -1,921 -732.0
Free Cash Flow - 2,769 14,875 -50,167 -6,202
FCF margin - 1,475.21% 26,097.29% -16,722.19% -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 29/06/21 29/06/21 22/04/22 10/04/23 20/03/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 - - - - -
Net Cash position 1 3,821 14,219 23,221 14,714 25,182
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - 2,769 14,875 -50,167 -6,202
ROE (net income / shareholders' equity) - 923% 378% -1,826% -38.5%
ROA (Net income/ Total Assets) - -32.6% -23.8% -28.7% -26.1%
Assets 1 - 41,047 132,347 59,391 33,912
Book Value Per Share 2 -1,221 -103,623 -8,819 1,539 2,194
Cash Flow per Share 2 649.0 50,695 3,241 332.0 1,207
Capex 1 72.6 264 1,170 328 840
Capex / Sales 17.24% 140.87% 2,052.22% 109.43% -
Announcement Date 29/06/21 29/06/21 22/04/22 10/04/23 20/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
PHAROS IBIO CO., LTD. Stock Pharos iBio Co., Ltd.
-27.51% 101M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.20% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.67% 113B
ARGENX SE Stock argenx SE
+18.95% 26.02B
BIONTECH SE Stock BioNTech SE
-23.86% 19.39B
GENMAB A/S Stock Genmab A/S
-19.03% 15.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.90% 15.09B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.14% 15.06B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+63.85% 14.93B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.49% 13.85B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A388870 Stock
  4. Financials Pharos iBio Co., Ltd.